证券代码：002773 证券简称：康弘药业 公告编号：2025-034 成都康弘药业集团股份有限公司 关于公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 近日，成都康弘药业集团股份有限公司（以下简称"公司"）子公 司成都康弘制药有限公司（以下简称"康弘制药"）收到国家药品监督 管理局签发的《药物临床试验批准通知书》。现将相关情况公告如下： 一、药品基本信息 药品名称：松龄血脉康胶囊 剂型：胶囊剂 拟增加功能主治：功能性室性早搏 注册分类：中药 2.3 类 受理号：CXZL2500018 审批结论：同意本品开展用于功能性室性早搏的临床试验。 二、产品简介 松龄血脉康胶囊为我公司独家品种，是我国首个以鲜松叶入药的 降压降脂中成药，已批准功能主治为"平肝潜阳，镇心安神。用于肝 1 / 2 阳上亢所致的头痛、眩晕、急躁易怒、心悸、失眠；高血压及原发性高 脂血症见上述证候者。"。本次新增功能主治临床试验申请的获批， 将有利于进一步提升产品的核心竞争力。 三、对公司的影响 由于药品从研发、临床试验、审评和审批的结果以及时间都具有 一定 ...

康弘药业(002773.SZ)公告称，公司子公司成都康弘制药有限公司收到国家药品监督管理局签发的《药 物临床试验批准通知书》，同意松龄血脉康胶囊开展用于功能性室性早搏的临床试验。松龄血脉康胶囊 为公司品种，已批准功能主治为"平肝潜阳，镇心安神。用于肝阳上亢所致的头痛、眩晕、急躁易怒、 心悸、失眠； 高血压及原发性高脂血症见上述证候者。" ...

Group 1 - The company Chengdu Kanghong Pharmaceutical Group Co., Ltd. has approved the use of idle funds to purchase financial products up to RMB 3.8 billion, focusing on high safety and liquidity products issued by commercial banks [1] - The investment decision will be executed by the company's president or financial officer, with the finance department responsible for the specific purchases [1] - The company has previously invested a total of RMB 2.245 billion in bank principal-protected financial products over the past twelve months, which is within the authorized investment limits [11] Group 2 - The company’s subsidiaries, Chengdu Kanghong Biotechnology Co., Ltd. and Sichuan Kanghong Pharmaceutical Trading Co., Ltd., have utilized their own funds to purchase financial products [2] - The financial products purchased include structured deposits from China Bank and Chengdu Bank, with specific details on expected returns and conditions outlined [4][7] - The expected annualized return for some products is between 0.79% and 3.17%, depending on market conditions and performance indicators [2][3]

成都康弘药业集团股份有限公司 关于使用自有资金购买理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"康弘药业"或"公司"） 第八届董事会第十次会议和二〇二四年度股东会审议通过了《关于使用 自有资金购买理财产品的议案》，同意公司及下属子公司使用部分闲置 自有资金在不超过人民币38亿元的额度内购买理财产品（包括结构性存 款），购买原则为安全性高、流动性好、由商业银行发行并提供保本承 诺的短期保本型理财产品（包括结构性存款），购买期限为自股东会审 议通过之日起一年；在上述额度及期限内，资金可以滚动使用；董事会 授权公司总裁或财务负责人根据上述原则行使具体理财产品的购买决策 权，由财务部负责具体购买事宜，具体内容详见公司指定信息披露媒体 和巨潮资讯网（www.cninfo.com.cn）刊登于2025年4月26日《第八届董 事会第十次会议决议公告》（公告编号：2025-010）、《关于使用自有 资金购买理财产品的公告》（公告编号：2025-014）及2025年5月22日《二 〇二四年度股东会决议公告》（公告编号：2 ...

Group 1 - The Alzheimer's concept sector increased by 3.80%, ranking 6th among concept sectors, with 29 stocks rising, including Hotgen Biotech, Jinkai Biotechnology, and Wohua Pharmaceutical, which rose by 18.15%, 9.25%, and 7.55% respectively [1] - The Alzheimer's concept sector saw a net inflow of 414 million yuan from main funds today, with 18 stocks receiving net inflows, and 5 stocks exceeding 30 million yuan in net inflow. Huahai Pharmaceutical led with a net inflow of 278 million yuan, followed by Kanghong Pharmaceutical, Meinian Health, and Hotgen Biotech [2][3] Group 2 - The top stocks in the Alzheimer's concept sector by net inflow ratio include Huahai Pharmaceutical, Dongya Pharmaceutical, and Kanghong Pharmaceutical, with net inflow ratios of 15.84%, 10.28%, and 9.61% respectively [3] - The trading performance of various stocks in the Alzheimer's concept sector shows significant activity, with Huahai Pharmaceutical and Kanghong Pharmaceutical leading in both net inflow and trading volume [4][5]

Core Viewpoint - The ophthalmology medical concept sector has shown a significant increase, with a rise of 3.08%, ranking it as the 10th highest among concept sectors, indicating strong market interest and investment potential in this area [1][2]. Group 1: Market Performance - As of June 3, the ophthalmology medical concept sector saw 42 stocks increase in value, with notable performers including Guanhao Biological, which hit a 20% limit up, and ST Zhongzhu, which also reached its limit up [1]. - Other top gainers in the sector included Nuo Si Lan De (up 18.82%), Hai Te Biological (up 13.18%), and Bei Da Pharmaceutical (up 7.34%) [1]. - Conversely, the sector experienced declines from companies such as Kanghong Pharmaceutical (down 2.16%), Chuangwei Digital (down 2.05%), and Jianghe Group (down 1.60%) [1]. Group 2: Capital Flow - The ophthalmology medical concept sector attracted a net inflow of 107 million yuan from major funds, with 25 stocks receiving net inflows, and 12 stocks exceeding 10 million yuan in net inflow [2]. - Guanhao Biological led the sector with a net inflow of 159 million yuan, followed by Bei Da Pharmaceutical (61.32 million yuan), Ma Ying Long (24.37 million yuan), and Hai Te Biological (21.22 million yuan) [2][3]. - The net inflow ratios for ST Zhongzhu, Huashen Technology, and Guanhao Biological were 15.16%, 13.41%, and 11.88%, respectively, indicating strong investor confidence in these stocks [3].

证券代码：002773 证券简称：康弘药业 公告编号：2025-032 成都康弘药业集团股份有限公司 关于使用自有资金购买理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"康弘药业"或"公司"） 第八届董事会第十次会议和二〇二四年度股东会审议通过了《关于使用 自有资金购买理财产品的议案》，同意公司及下属子公司使用部分闲置 自有资金在不超过人民币38亿元的额度内购买理财产品（包括结构性存 款），购买原则为安全性高、流动性好、由商业银行发行并提供保本承 诺的短期保本型理财产品（包括结构性存款），购买期限为自股东会审 议通过之日起一年；在上述额度及期限内，资金可以滚动使用；董事会 授权公司总裁或财务负责人根据上述原则行使具体理财产品的购买决策 权，由财务部负责具体购买事宜，具体内容详见公司指定信息披露媒体 和巨潮资讯网（www.cninfo.com.cn）刊登于2025年4月26日《第八届董 事会第十次会议决议公告》（公告编号：2025-010）、《关于使用自有 资金购买理财产品的公告》（公告编号：2025-01 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-031 成都康弘药业集团股份有限公司 关于使用自有资金购买理财产品的公告 近日，公司子公司成都康弘生物科技有限公司（以下简称"康弘生 物"）使用自有资金购买了理财产品。现将有关情况公告如下： 一、购买理财产品情况 中国银行理财产品的主要内容 所属银行 中国银行成都武侯支行 1/6 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"康弘药业"或"公司"） 第八届董事会第十次会议和二〇二四年度股东会审议通过了《关于使用 自有资金购买理财产品的议案》，同意公司及下属子公司使用部分闲置 自有资金在不超过人民币38亿元的额度内购买理财产品（包括结构性存 款），购买原则为安全性高、流动性好、由商业银行发行并提供保本承 诺的短期保本型理财产品（包括结构性存款），购买期限为自股东会审 议通过之日起一年；在上述额度及期限内，资金可以滚动使用；董事会 授权公司总裁或财务负责人根据上述原则行使具体理财产品的购买决策 权，由财务部负责具体购买事宜，具体内容详见公司指定信息披露媒体 和 ...

Core Viewpoint - The ophthalmology medical concept sector has shown a positive performance, with a 1.30% increase, ranking fifth among concept sectors, driven by significant gains in several stocks [1][2]. Group 1: Sector Performance - The ophthalmology medical concept sector saw 28 stocks rise, with notable performers including Innovation Medical, *ST Jingfeng, and others reaching their daily limit up [1]. - Key gainers in the sector included Innovation Medical (+14.87%), Guanhao Biological (+8.88%), and Kanghong Pharmaceutical (+7.84%) [1]. - Conversely, the sector also experienced declines, with major losers being Skyworth Digital (-3.19%), Jincheng Pharmaceutical (-2.40%), and Doctor Eye Glasses (-2.10%) [1]. Group 2: Capital Flow - The ophthalmology medical concept sector attracted a net inflow of 208 million yuan, with 23 stocks receiving net inflows, and 8 stocks exceeding 10 million yuan in net inflow [2]. - The leading stock in terms of net capital inflow was Innovation Medical, which saw a net inflow of 378 million yuan, followed by Kanghong Pharmaceutical and Hengfeng Information with net inflows of 66.97 million yuan and 46.49 million yuan, respectively [2][3]. - The net inflow ratios for top stocks included Innovation Medical (26.37%), *ST Jingfeng (17.55%), and Hengfeng Information (13.55%) [3].

智通财经5月30日电，创新药概念股盘中持续走强，万邦德、康弘药业、千红制药、华森制药、哈三 联、联化科技、海南海药、华纳药厂、睿智医药等10余股涨停，舒泰神、科兴制药、冠昊生物等涨超 10%。 创新药概念股持续走高 万邦德等10余股涨停 ...